The Gaps — Public Health

A "gap" in this analysis is the distance between the formal legal architecture of a public-health program and the actual receipt it produces for a PA-3 constituent. Each sub-domain has its own gap analysis drawn from documented design features applied to documented PA-3 conditions. The patterns recur across sub-domains. D2's distinctive analytical contribution is the aggregate finding that PA-3 constituents face federal public-health architecture in a period of substantial restructuring partially constrained by courts, with state and local layers selectively diverging where state-AG coalitions or state-administered programs provide functional alternatives, and with structural pressure on the safety-net institutions most heavily relied upon by lower-income PA-3 constituents. The Braidwood resolution preserves a critical preventive-services baseline; the Murphy injunction restores the pre-2026 vaccine schedule baseline; the IRA negotiation program continues; the DEA Schedule III rescheduling opens a § 280E relief pathway. These are substantive bright spots within an otherwise aggressive rollback context.

The recurring patterns

Four cross-cutting findings appear across the seven sub-domains.

Pattern 1 — Federalism stress as a structural feature. The pattern that authorizing statutes provide permanent or quasi-permanent appropriations while Congressional appropriators repeatedly redirect or rescind those appropriations to offset other priorities operates across multiple federal public-health funding streams. PPHF cumulative rescissions FY13-FY27 reach approximately $11.85 billion (specific by P.L.: 112-96 at $6.25 billion; 114-255 at $3.5 billion; 115-96 at $750 million; 115-123 at $1.35 billion); FY26 PPHF elimination is a Trump budget proposal pending Congressional action. § 330 Community Health Center Fund mandatory funding was extended only through December 2026 via the 2026 Consolidated Appropriations Act, with no multi-year reauthorization despite advocate push. Title V FY26 specific PA allotment is partially unverified. The federalism stress is operative across the Infrastructure, Maternal & Child Health, and Health Access sub-domains.

Pattern 2 — MAHA-era institutional restructuring (refined to "aggressive rollback under court constraint plus selective preservation under political pragmatism"). Aggressive rollback elements include the FDA reduction in force plus CDC Immunization Services Division termination; the HHS mRNA vaccine wind-down (August 5, 2025; 22 BARDA contracts terminated; approximately $500 million); the ACIP firing and reconstitution plus the Decision Memo schedule reduction (January 5, 2026) plus the ACIP charter renewal (April 9, 2026); the chain of three Trump EOs revoking the federal EJ framework plus EJScreen offline and EPA EJ offices closed in all 10 regions. Court-imposed checks operative in the verification window include the Murphy preliminary injunction (March 16, 2026; D. Mass.; stayed the schedule reduction, blocked the reconstituted ACIP, overturned the May 2025 COVID-19 directive); the Rhode Island injunction (D.R.I., Judge DuBose; narrowed August 12, 2025 to protect FDA CTP and most CDC offices but excluding CDC ISD which was terminated); and the Braidwood SCOTUS resolution (June 27, 2025) preserving the ACA § 2713 preventive-services mandate. Selective preservation under political pragmatism includes IRA Round 1 effective January 1, 2026; Round 2 finalized for January 1, 2027; Round 3 in progress under Trump EO 14273 (April 15, 2025) which directs modifications without dismantling; DEA Schedule III rescheduling for state-licensed medical cannabis (April 22-28, 2026) opening a substantive § 280E relief pathway. Continued institutional churn (CBER leadership Marks → Prasad → next) signals institutional instability complicating day-to-day operational continuity even where programs formally continue.

Pattern 3 — State and local divergence patterns. Where federal architecture is rolling back, states and localities are diverging from the federal default in selective areas. State-AG coalitions as a litigation channel: the 19-state coalition in State of RI v. Trump (Judge DuBose); the 15-state coalition led by Minnesota AG Ellison parallel-suing on the January 5, 2026 Decision Memo; AAP-led plaintiffs in AAP v. Kennedy (Judge Murphy) including the Massachusetts Public Health Alliance. Substitute infrastructure for federal capacity: 16+ states have state-level EJ mapping tools as EJScreen substitutes (Maryland, Massachusetts, Minnesota named); Harvard and Public Environmental Data Partners host EJScreen reconstructions; a PA-specific state EJ mapping tool was not specifically located. State-scale naloxone distribution at substantial scale: the PA Overdose Prevention Program distributed approximately 800,000 naloxone doses plus 737,000 test strips plus approximately 9,500 reversals in 2025. PA-specific posture: PA continues operating under existing 28 Pa. Code Chapter 23 Subchapter C without divergent state announcement post-Murphy; PA continues not having an adult-use cannabis program (so § 280E apportionment-complication does not affect PA operators); PA remains operationally aligned with federal default in vaccine policy and is not a state-AG coalition leader on schedule litigation.

Pattern 4 — Institutional capacity and safety-net structural pressure under federal Medicaid uncertainty (refined toward "structural pressure manageable in the near term but multi-year exposure to Medicaid retrenchment"). Temple Health recharacterized from "closure-scenario indicators" to "operational financial pressure under federal Medicaid uncertainty." Temple FY25 (year ending June 30, 2025) $22 million operating profit on $3.3 billion in revenue (+15%); Q1 FY26 $15 million operating loss improved from $17 million prior year; investment-grade BBB rating maintained; FY26 capital trim of $10-15 million to $60-65 million total directly attributed to federal Medicaid uncertainty; strategic investments continuing (Fox Chase oncology; Juniata Women & Families Hospital). Not in closure-scenario territory. Einstein operationally part of Jefferson Health since the 2021 merger; standalone Einstein framing is anachronistic. FQHC § 330 mandatory funding extended through December 2026; no multi-year reauthorization; OBBBA Medicaid cuts threaten 40%+ of FQHC revenue multi-year; CHC operating margins average below -2% with under 90 days cash on hand; 1,512 CHCs nationally serve 34M to 52M Americans annually. Hahnemann closure (2019) remains the structural-precedent reference for safety-net system fragility under federalism stress; verified context indicates current safety-net institutions are stressed but stable in the near term, with multi-year exposure.

Gaps by sub-domain

Each sub-domain's full gap analysis lives on its own page. Brief summaries below.

Sub-Domain 1 · Public Health Infrastructure & Governance

PPHF authorizing-statute / appropriated-funding mismatch (cumulative rescissions FY13-FY27 approximately $11.85 billion; FY26 elimination proposed). Capacity erosion via FDA RIF (approximately 18% of workforce; approximately 25% HHS aggregate with voluntary separations) and CDC ISD termination (after the Rhode Island injunction's August 12, 2025 narrowing). PHEP/ELC operational reliance with FY26 uncertainty. PA Disease Prevention and Control Law operational structure. USDA ERS data-infrastructure rollback. Governance disruption via ACIP charter rewrite plus Decision Memo schedule reduction (two distinct events; both stayed by the Murphy injunction blocking the reconstituted ACIP). Read the full analysis →

Sub-Domain 2 · Communicable Disease Control

PHEP/ELC operational reliance for PDPH surveillance. PA reportable-disease infrastructure under 28 Pa. Code § 27 et seq. ACIP charter rewrite implementation impact on VFC and federal-program coverage (Moderna mRNA flu, Pfizer/Valneva Lyme, RSV vaccines for adults 18-49 face an uncertain recommendation pathway). Childhood schedule litigation under court check (AAP v. Kennedy, D. Mass., Judge Murphy; HHS appealed to 1st Cir.). PA school-entry schedule decision moot under restored federal default (28 Pa. Code Chapter 23 Subchapter C operative). Braidwood-dependent treatment access preserved (PrEP, USPSTF cancer screenings, tobacco cessation, STI screenings nationwide). Sub-domain page →

Sub-Domain 3 · Maternal & Child Health

Title V federal-state-local pathway architecture (PA-specific allotment plus PDPH MCFH sub-allocation partially unverified). PA Maternal Mortality Review Committee operational structure (current reporting cycle partially unverified). PA Newborn Screening Program coverage (statutory framework verified at 28 Pa. Code § 28.4). Perinatal preventive services post-Braidwood (closed; ACA § 2713 mandate upheld nationwide). Title V FY26 funding pipeline (federal annual-appropriation process is the operative mechanism). Childhood schedule restoration impact on PA pediatric immunization (Murphy injunction restores hep B birth-dose recommendation). Sub-domain page →

Sub-Domain 4 · Chronic & Non-Communicable Disease

USPSTF preventive services plus chronic-disease screening Braidwood-resolved. Braidwood-dependent treatment access for chronic disease closed. IRA MFP first-round savings reach bounded by approximately 13% non-LIS / approximately 18% LIS utilization rates. CTP rule-making capacity vs. FDA RIF (CTP protected by Rhode Island injunction; menthol withdrawal proceeded). OBBBA orphan-drug exclusion impact on IRA selection (Keytruda and Opdivo delayed in Round 3). PA Cancer Plan operational structure (Cancer Registry currency partially unverified). Standard 17 governmental-score handling: D12-derived CBO February 2026 baseline preserved as supplementary citation; primary CMS architectural finding stands. Sub-domain page →

Sub-Domain 5 · Environmental Health

Federal-state-local environmental statutory architecture confirmed (CAA, SDWA, RLPHRA, CERCLA; PA APCA, PA SDWA, PA Act 2, PA HSCA, PA Act 44; PA Const. Art. I § 27 plus PEDF). PA-3-specific contaminant burden under federal/state framework confirmed at structural level; tract-level current figures limited by EJScreen takedown. EJScreen accessibility recharacterized — tool offline on epa.gov since March 2025; Harvard plus PEDP reconstructions exist; EPA enforcement use prohibited. PWD LCRR compliance status (LSL inventory plus replacement schedule) partially unverified. EJ EO revocation impact on PA-3 federal funding pipeline plus analytical capacity recharacterized: three-EO chain (EO 14148, EO 14151, EO 14173); EPA EJ offices closed in 10 regions including Region III; grant clawbacks underway; PA-3-specific project funding clawback specifics partially unverified. Philadelphia Lead Disclosure operational structure confirmed. This is the most substantively widened gap of the seven sub-domains in the verification cycle. Sub-domain page →

Sub-Domain 6 · Health Access, FQHCs & SDOH

PA-3 FQHC patient/provider density vs. HPSA shortage (PA-3-specific UDS plus HPSA tract-level currency partially unverified). Title VI / EO 13166 language access enforcement (OCR enforcement-posture partially unverified). FQHC capacity vs. HPSA shortage gap updated (§ 330 extended through December 2026; no multi-year reauthorization; OBBBA Medicaid cuts threaten capacity multi-year). Hospital financial fragility recharacterized from "closure-scenario indicators" to "operational financial pressure under federal Medicaid uncertainty" — Temple FY25 $22 million profit; investment-grade BBB maintained; Einstein-as-Jefferson post-2021. Medicaid managed care outsourcing pattern. 340B plus IRA plus § 9007 reporting interaction updated (HRSA 340B rebate pilot launched January 1, 2026; 85% of 2026 NDCs have lower 340B ceiling than MFP). Sub-domain page →

Sub-Domain 7 · Substance Use & Harm Reduction

CSA § 856 federal supervised-consumption block continuing (Safehouse June 2024 3d Cir. appeal pending). Recent OD mortality decline trajectory updated (Philadelphia 2024 1,045; 2025 preliminary 747 through December 23; PA statewide 29% decline 2024 → 2025). Kensington supply chemistry transition verified to peer-reviewed source (Hochstatter et al.; medetomidine 83% by March 2025; BTMPS 25%; "demon" displacing "tranq"). Prevention Point operating authority under PA Act 66 of 2021. DEA Schedule III licensee 60-day priority window. Race-disparate overdose mortality mechanism reinforced (Black rates continuing to rise through 2024 while White rates declined). DBHIDS single-MCO BH straddling SUD. § 280E retrospective relief guidance pending IRS — prospective relief confirmed for full 2026 calendar year for state-licensed medical cannabis; apportionment rules pending; retrospective relief not yet committed by Treasury. Mayor Parker / Kensington Wellness Court structural framing (217 arrested; 72 accepted; 10 completed; 1 of 10 OD'd; two-thirds bench warrants). Sub-domain page →

The aggregate finding

PA-3 constituents face federal public-health architecture in a period of substantial restructuring partially constrained by courts, with state and local layers selectively diverging where state-AG coalitions or state-administered programs (PA Overdose Prevention Program; existing PA school immunization framework) provide functional alternatives, but with structural pressure on the safety-net institutions (Temple Health; PA-3 FQHCs) most heavily relied upon by lower-income PA-3 constituents. The Braidwood resolution preserves a critical preventive-services baseline; the Murphy injunction restores the pre-2026 vaccine schedule baseline; the IRA negotiation program continues under Trump EO 14273's modification framing; the DEA Schedule III rescheduling opens a § 280E relief pathway. These are substantive bright spots within an otherwise aggressive rollback context.

The court-imposed checks preserve statutory promises but do not restore institutional capacity that has been terminated outright. The Rhode Island injunction's August 12, 2025 narrowing specifically excluded CDC ISD and PVEB from protection; those offices were terminated, and the federal capacity for state-level immunization equity support is no longer present. The EPA Office of EJ closure included EJ units in all 10 regions including Region III; the federal analytical and enforcement infrastructure for EJ-relevant work has been substantially redirected, with substitute reconstructions at Harvard and Public Environmental Data Partners that are not federally administered.

PA continues operating under existing state architecture (PA Disease Prevention and Control Law of 1955; PA Air Pollution Control Act; PA SDWA; PA Constitutional Article I § 27 plus PEDF; PA Medical Marijuana Act; PA Act 66 of 2021 SSP authorization) without divergent state announcement on the most contested federal events. PA-3 constituents continue to receive most of the protections that the statutory architecture promises, with two qualifications: the institutional capacity behind those protections has been operationally degraded in ways not always visible to most residents, and the funding architecture sits within multi-year exposure (PPHF; FQHC § 330 December 2026 reauthorization horizon; Title V FY26 PA allotment unverified; OBBBA Medicaid cuts threatening safety-net stability).

What follows from this

Three policy implications follow from the gap pattern.

The first is a question of which gaps are within reach of which actors. Some gaps — PHEP/ELC FY26 levels; § 330 reauthorization beyond December 2026; PPHF FY26 elimination decision; OBBBA Medicaid implementation timeline; IRA Round 3 selections; the Trump administration's enforcement posture at ED OCR, EPA OECA, and HHS OCR; the Murphy and Rhode Island injunction appeals in the First Circuit — sit within congressional authority and federal-rule-making. Others — PA-specific state EJ mapping tool development; PA divergent-position decisions if the First Circuit reverses Murphy; PA Cancer Plan currency; PWD LCRR compliance implementation; PA county-level SSP implementation; PA Overdose Prevention Program scale — sit within Pennsylvania state administrative authority. Local levers — PDPH MCFH sub-allocation; AACO Philadelphia EMA Ryan White Part A planning; DBHIDS HealthChoices Behavioral Health single-MCO operations; Kensington Wellness Court program design — operate within Philadelphia administrative authority. The federal House representation lever operates at the appropriations and rule-making interface; state and local levers operate at the implementation and administrative-discretion interfaces.

The second is a question of administrative infrastructure. The MAHA-era institutional restructuring concentrates harm at the institutional-capacity interface rather than at the statutory-protection interface — Braidwood and Murphy preserved the statutory promises, but CDC ISD termination, EPA EJ office closures, and FDA workforce reduction operationally diminished federal capacity in ways that litigation has not restored. Investment in state-level substitute infrastructure (a PA-specific EJ mapping tool; PA Cancer Registry currency; PA Disability Determination Services throughput; statewide naloxone distribution scale) becomes structurally more important when federal partnership capacity is degraded. State-AG coalition participation in litigation (PA is not currently a leader in state-AG litigation challenging federal rollback) is a structural lever PA has not yet exercised.

The third is a question of accountability documentation. Several gaps documented here — PA-3 FQHC UDS data plus HPSA tract-level currency; PA-3-specific EJ project funding clawback specifics; PA-3 tract-level OD mortality figures for 2025; PWD LCRR LSL inventory completion plus replacement schedule; childhood blood-lead surveillance currency; PDPH FY26 budget actuals; PA Cancer Registry currency for PA-3-specific tracts; Title V FY26 PA allotment plus PDPH MCFH sub-allocation; PA MMRC current reporting cycle currency; AACO Philadelphia EMA Ryan White Part A FY26 allocation — would be partially closed by routine public disclosure rather than program reform. Several structural inferences in this domain remain inferences rather than measured outcomes because the data needed to measure them at the PA-3 sub-area scale is not consistently published or accessible. The verified file's F-flag inventory catalogues the institutional-retrieval items the next verification cycle will address.